Regulatory Affairs

      Cybin Receives Regulatory Approval for First-in-Human Clinical Trial of CYB004 DMT Molecule

      Cybin Inc., a leading psychedelic pharmaceutical company, recently announced that it has received regulatory approval for its first-in-human clinical trial of its CYB004 molecule,...

      FDA Grants Orphan-Drug Exclusivity to Xeris Biopharma’s Recorlev®

      The U.S. Food and Drug Administration (FDA) recently granted orphan-drug exclusivity to Xeris Biopharma’s Recorlev® for the treatment of hypoglycemia in adults with diabetes....

      Recent Articles

      Get a free copy of "Cracking the Generics Code"

      Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.